Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors

NCT01822756 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT01822756
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01822756 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Lead sponsor
Incyte Corporation
Phase
Phase 1
Overall status
Terminated
Start date
April 30, 2013
Completion date
August 31, 2016
Enrollment
42 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer, solid tumors